Ligand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/31/22
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire • 10/26/22
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 10/03/22
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-OffBusiness Wire • 10/03/22
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaBusiness Wire • 08/24/22
Ligand Pharmaceuticals, Inc. (LGND) CEO John Higgins on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 08/01/22
Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/22